Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Provided By GlobeNewswire
Last update: Jul 9, 2025
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM)
Read more at globenewswire.com
